Novartis (NVS) announced that it has successfully completed its acquisition of Tourmaline Bio (TRML). With the completion of the acquisition, shares of the common stock of Tourmaline have ceased trading on the Nasdaq Stock Market and Tourmaline is now an indirect wholly owned subsidiary of Novartis. “The acquisition of Tourmaline Bio aligns with our strategy to deepen expertise in areas where Novartis can lead and add value in cardiovascular innovation. Pacibekitug’s differentiated anti-IL-6 mechanism offers a scientifically compelling approach to residual inflammation – a key driver of atherosclerotic cardiovascular disease. We look forward to collaborating with Tourmaline’s team to further advance this promising asset and continue strengthening our ability to deliver potentially transformative therapies for diseases with high unmet need,” said Shreeram Aradhye, M.D., President of Development and Chief Medical Officer at Novartis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Novartis announces expiration of Tourmaline Bio tender offer
- Tourmaline Bio’s Promising Phase 2b Study on Thyroid Eye Disease Treatment
- Novartis announces expiration of HSR Act waiting period of Tourmaline Bio offer
- Novartis Stock (NVS) Pops as U.S. Approves Pill to Treat Stubborn Skin Flare-Ups
- Monte Rosa’s Stock (GLUE) Skyrockets on $5.7B Deal with Novartis